These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 1870211)

  • 21. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    Hsu KH; Lubeck MD; Davis AR; Bhat RA; Selling BH; Bhat BM; Mizutani S; Murphy BR; Collins PL; Chanock RM
    J Infect Dis; 1992 Oct; 166(4):769-75. PubMed ID: 1527411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis.
    Dakhama A; Vitalis TZ; Hegele RG
    Eur Respir J; 1997 Jan; 10(1):20-6. PubMed ID: 9032486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of the humoral immune response on the pathogenesis of respiratory syncytial virus (RSV) infection].
    Streckert HJ; Humbert B; Philippou S; Forster J
    Immun Infekt; 1993 Jun; 21(3):75-7. PubMed ID: 8335338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.
    Tripp RA; Moore D; Winter J; Anderson LJ
    J Virol; 2000 Feb; 74(4):1614-22. PubMed ID: 10644330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics of in vitro production of mucosal antibody to respiratory syncytial virus in tonsillar tissue lymphocytes.
    Okamoto Y; Brodsky L; Bernstein JM; Ogra PL
    Clin Immunol Immunopathol; 1988 Nov; 49(2):299-307. PubMed ID: 2458875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of respiratory syncytial virus with human cord blood mononuclear cells.
    Kositanont U; Vuddhakul V; Kositanont C; Thong YH
    Asian Pac J Allergy Immunol; 1992 Dec; 10(2):135-9. PubMed ID: 1305815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Respiratory syncytial virus and immune response: from the diagnosis of infection to prospects of vaccination].
    Pothier P
    Pediatrie; 1991; 46(8-9 Suppl):1-4. PubMed ID: 1665219
    [No Abstract]   [Full Text] [Related]  

  • 29. Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.
    Goestch L; Plotnicky-Gilquin H; Champion T; Beck A; Haeuw JF; Nguyen T; Bonnefoy JY; Corvaïa N
    Vaccine; 2000 Jun; 18(24):2648-55. PubMed ID: 10781850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    McGinnes Cullen L; Schmidt MR; Morrison TG
    J Virol; 2019 May; 93(9):. PubMed ID: 30760576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults.
    Falsey AR; Walsh EE
    J Infect Dis; 1998 Feb; 177(2):463-6. PubMed ID: 9466538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.
    Kulkarni AB; Connors M; Firestone CY; Morse HC; Murphy BR
    J Virol; 1993 Feb; 67(2):1044-9. PubMed ID: 8419638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
    Johnson PR; Olmsted RA; Prince GA; Murphy BR; Alling DW; Walsh EE; Collins PL
    J Virol; 1987 Oct; 61(10):3163-6. PubMed ID: 3305988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection.
    Srikiatkhachorn A; Braciale TJ
    J Virol; 1997 Jan; 71(1):678-85. PubMed ID: 8985399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG-subclass-specific antibody reactivity to respiratory syncytial virus polypeptides investigated by western blot.
    Jankowski M; Hornsleth A; Olsen PG
    Res Virol; 1990; 141(3):343-53. PubMed ID: 2392617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation by respiratory syncytial virus-infected cells.
    Edwards KM; Snyder PN; Wright PF
    Arch Virol; 1986; 88(1-2):49-56. PubMed ID: 3954599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary pulmonary murine cytotoxic T lymphocyte specificity in respiratory syncytial virus pneumonia.
    Gupta R; Yewdell JW; Olmsted RA; Collins PL; Bennink JR
    Microb Pathog; 1990 Jul; 9(1):13-8. PubMed ID: 2077342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique.
    Roca A; Abacassamo F; Loscertales MP; Quintó L; Gómez-Olivé X; Fenwick F; Saiz JC; Toms G; Alonso PL
    J Med Virol; 2002 Aug; 67(4):616-23. PubMed ID: 12116014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
    Hildreth SW; Baggs RR; Brownstein DG; Castleman WL; Paradiso PR
    Vaccine; 1993; 11(6):615-8. PubMed ID: 8322482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.